Back to Journals » Clinical Epidemiology » Volume 2

Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue

Authors Ahern T, Christensen M, Cronin-Fenton DP, Lunetta KL, Rosenberg CL, Sørensen HT, Lash TL, Hamilton-Dutoit S

Published 22 October 2010 Volume 2010:2 Pages 241—246

DOI https://doi.org/10.2147/CLEP.S13811

Review by Single-blind

Peer reviewer comments 2


Thomas P Ahern1, Mariann Christensen2, Deirdre P Cronin-Fenton3, Kathryn L Lunetta4, Carol L Rosenberg5, Henrik Toft Sørensen3, Timothy L Lash3, Stephen Hamilton-Dutoit2
1Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts; 2Institute of Pathology; 3Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; 4Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts; 5Hematology/Oncology Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA

Objectives: Translational epidemiology studies often use archived tumor specimens to evaluate genetic hypotheses involving cancer outcomes. When the exposure of interest is a germline polymorphism, a key concern is whether the genotype assayed from tumor-derived DNA is representative of the germline. We evaluated the concordance between breast tumor-derived and normal lymph node-derived genotypes for three polymorphic tamoxifen-metabolizing enzymes.
Methods: We assayed paired DNA samples extracted from archived tumor and normal lymph node tissues from 106 breast cancer patients. We used TaqMan assays to determine the genotypes of three enzyme variants hypothesized to modify tamoxifen effectiveness, ie, CYP2D6*4, UGT2B15*2, and UGT1A8*2. We assessed genotype agreement between the two DNA sources by calculating the percent agreement and the weighted kappa statistic.
Results: We successfully obtained genotypes for CYP2D6*4, UGT2B15*2, and UGT1A8*2 in 99%, 100%, and 84% of the paired samples, respectively. Genotype concordance was perfect for the CYP2D6*4 and UGT1A8*2 variants (weighted kappa for both = 1.00; 95% confidence interval [CI] 1.00, 1.00). For UGT2B15*2, one pair out of 106 gave a discordant result that persisted over several assay repeats.
Conclusions: We observed strong agreement between DNA from breast tumors and normal lymphatic tissue in the genotyping of polymorphisms in three tamoxifen-metabolizing enzymes. Genotyping DNA extracted from tumor tissue avoids the time-consuming practice of microdissecting adjacent normal tissue when other normal tissue sources are not available. Therefore, the demonstrated reliability of tumor-derived DNA allows resources to be spent instead on increasing sample size or the number of polymorphisms examined.

Keywords: molecular epidemiology, breast neoplasms, cytochrome P450 CYP2D6, glucuronosyltransferase

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]